GenSight Biologics S.A. (SIGHT.PA)
Develops gene therapies to restore vision in people with inherited eye diseases.
0.08-0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-42.1%
The outlook
GenSight Biologics trades near its 52-week low, well below both its 50- and 200-day averages, suggesting a prolonged downtrend. Analyst coverage is sparse at two firms, though the consensus leans Buy with an average target implying significant upside from current levels. The overall picture reflects a deeply depressed stock with modest analyst support.
What’s behind the score
Analyst consensusBuy — 2.3 avg of 2 analysts
Price trendBelow its 50- & 200-day averages
52-week range4% of the way from its 52-week low to high
Price targetAvg target +271% vs current price
Analyst price target
~12-month · 2 analysts0.31average target+271.0% vs now
Now 0.08
Low 0.21High 0.40
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$19.3M
52-wk high
0.24
52-wk low
0.08
50-day avg
0.08
200-day avg
0.09
Trailing P/E
—